Shots:

• Intravacc signs an agreement with EpiVax for the development of novel vaccine against COVID-19- based on Intravacc's Outer Membrane Vesicles (OMV) technology platform
• The collaboration will combine Intravacc's OMV delivery platform with synthetically produced COVID-19 epitopes from EpiVax' immunoinformatics toolbox. The focus of the collaboration is to generate safe and effective adaptive immunity against SARS-CoV-2 and related coronaviruses
• The company will immediately initiate preclinical studies to select the best candidate peptides for the vaccine. Intravacc will utilize its in-house pilot-scale facility for the GMP production of the OMV-peptide vaccine and anticipates the P-I studies to be initiated in Q4’20

Click here to read full press release/ article | Ref: PRNewswire | Image: Behance